Bilaterale Vaskulitis nach einmaliger Gabe von Brolucizumab

• Literatur

• 1 Holz FG, Heinz C, Wolf A. et al. Intraokulare Entzündungen bei Brolucizumab-Anwendung: Patientenmanagement – Diagnose – Therapie. Ophthalmologe 2021; 118: 248-256
• 2 Baumal CR, Bodaghi B, Singer M. et al. Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and/or Vascular Occlusion after Brolucizumab Treatment. Ophthalmol Retina 2020;
• 3 Dugel PU, Koh A, Ogura Y. et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology 2020; 127: 72-84
• 4 Nguyen QD, Das A, Do DV. et al. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration. Ophthalmology 2020; 127: 963-976
• 5 Witkin AJ, Hahn P, Murray TG. et al. Brolucizumab-Associated Intraocular Inflammation in Eyes Without Retinal Vasculitis. J Vitreoretin Dis 2021; 5: 326-332
• 6 Iyer PG, Peden MC, Suner IJ. et al. Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study. Am J Ophthalmol Case Rep 2020; 20: 100989
• 7 Kessler LJ, Mayer CS, Son HS. et al. [Bilateral vasculitis following intravitreal brolucizumab injection]. Ophthalmologe 2021;
• 8 Haug SJ, Hien DL, Uludag G. et al. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep 2020; 18: 100680
• 9 Angerer MPM, Neuburger M, Hille K. et al. [Vaso-occlusive retinitis following intravitreal injection of brolucizumab]. Ophthalmologe 2020;
• 10 Baumal CR, Spaide RF, Vajzovic L. et al. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab. Ophthalmology 2020; 127: 1345-1359